NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.910
-0.010 (-0.52%)
At close: Sep 30, 2026, 4:00 PM EDT
1.880
-0.030 (-1.57%)
After-hours: Sep 30, 2026, 6:20 PM EDT
NervGen Pharma Earnings Call Transcripts
Fiscal Year 2026
-
NVG-291 is advancing in a pivotal phase III trial for chronic cervical spinal cord injury, showing significant safety and efficacy in earlier studies, with durable improvements in hand function and quality of life. The program has strong FDA alignment, robust patient advocacy, and potential for expansion into other CNS disorders.
-
NVG-291, a peptide therapy for chronic cervical spinal cord injury, showed significant functional and quality-of-life improvements in the CONNECT trial, with a strong safety profile. The upcoming RESTORE phase III trial is designed for regulatory approval, targeting a large unmet need and leveraging a cost-efficient, scalable approach.